Home/Pipeline/ADPO-002

ADPO-002

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Adipo Therapeutics

About Adipo Therapeutics

Adipo Therapeutics is a private, preclinical-stage biotech founded in 2018, targeting obesity through a first-in-class mechanism. The company's platform utilizes nanotechnology to deliver Notch inhibitors, aiming to 'brown' white fat and increase resting metabolic rate, as demonstrated in preclinical and ex-vivo human tissue studies. Leveraging talent from Indiana's academic and pharmaceutical ecosystem, Adipo is positioning itself to address the massive unmet need in the metabolic disease market with a therapy focused on energy expenditure rather than appetite suppression.

View full company profile

Therapeutic Areas

Obesity Metabolic Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active